Compare MRNA & VRSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRNA | VRSK |
|---|---|---|
| Founded | 2010 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 24.7B |
| IPO Year | 2018 | 2008 |
| Metric | MRNA | VRSK |
|---|---|---|
| Price | $54.19 | $201.46 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 13 |
| Target Price | $34.27 | ★ $259.38 |
| AVG Volume (30 Days) | ★ 6.9M | 1.7M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.06% |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | ★ $19,263,000,000.00 | N/A |
| Revenue This Year | $9.36 | $6.68 |
| Revenue Next Year | $15.43 | $6.74 |
| P/E Ratio | ★ N/A | $111.66 |
| Revenue Growth | ★ 4.29 | N/A |
| 52 Week Low | $22.28 | $155.94 |
| 52 Week High | $85.60 | $300.93 |
| Indicator | MRNA | VRSK |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 62.55 |
| Support Level | $45.69 | $197.29 |
| Resistance Level | $54.50 | $205.70 |
| Average True Range (ATR) | 3.73 | 5.85 |
| MACD | -2.47 | 0.32 |
| Stochastic Oscillator | 1.27 | 79.98 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Verisk is a leading data, analytics, and technology provider for property-casualty insurers. Verisk traces its history to Insurance Services Office, a nonprofit advisory organization founded in 1971 by US P&C insurers. ISO was formed as an association of insurance companies to assist with a variety of insurance use cases, such as reporting to regulators, defining policies, and determining independent premium rates. As the firm expanded its use cases, it became a for-profit company, renamed Verisk, and went public in 2009. Verisk's single segment (insurance) provides underwriting solutions, including forms, rules, loss costs, and catastrophe modeling. For claims, Verisk's solutions include property repair estimates and antifraud tools. About 83% of Verisk's revenue is US-based.